About The Trial

Depression is much more common — four times, in fact — in patients with end-stage renal disease who are on hemodialysis. Unfortunatly, it is often undiagnosed or, when diagnosed, not treated.

In short, the ASCEND trial will see if cognitive behavioral therapy or drug therapy help improve depression in these patients. It will also see if these therapies help patients feel more supported, sleep better, have more energy and more. In addition, the study will look at whether an initial discussion about their depressive symptoms and different options for treatment of depression available to them helps patients accept treatment. The study will also follow the depressive symptoms in patients who don’t accept any form of treatment.

Right now, some patients are reluctant to accept treatment for depression. They don’t wish to take another pill or go to a therapist appointment on top of all their other appointments. One unique part of this study is that patients will have cognitive behavioral therapy during dialysis — currently, patients must see therapists outside of dialysis.

We hope this study will give us information about these treatments to see if they do help dialysis patients with depression, and to see if cognitive behavioral therapy is better-received in the dialysis facility.

Learn more about cognitive behavioral therapy and drug therapy and how they will be used in this trial.

Learn about the literature associated with this study

You can also view the full description of the trial at clinicaltrials.gov.